KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Cash & Equivalents (2016 - 2025)

Opko Health (OPK) has disclosed Cash & Equivalents for 16 consecutive years, with $369.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 14.55% year-over-year to $369.1 million, compared with a TTM value of $369.1 million through Dec 2025, down 14.55%, and an annual FY2025 reading of $369.1 million, down 14.55% over the prior year.
  • Cash & Equivalents was $369.1 million for Q4 2025 at Opko Health, down from $415.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $436.0 million in Q1 2025 and bottomed at $40.6 million in Q2 2024.
  • Average Cash & Equivalents over 5 years is $214.9 million, with a median of $143.6 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents crashed 62.47% in 2024, then soared 569.65% in 2025.
  • Year by year, Cash & Equivalents stood at $134.7 million in 2021, then grew by 13.72% to $153.2 million in 2022, then plummeted by 37.41% to $95.9 million in 2023, then surged by 350.49% to $431.9 million in 2024, then fell by 14.55% to $369.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for OPK at $369.1 million in Q4 2025, $415.2 million in Q3 2025, and $271.7 million in Q2 2025.